Search

Your search keyword '"Shah, Jatin"' showing total 3,457 results
Start Over Author "Shah, Jatin"
3,457 results on '"Shah, Jatin"'

3. Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment.

Author

Baljevic, Muhamed, Gasparetto, Cristina, Schiller, Gary, Tuchman, Sascha, Callander, Natalie, Lentzsch, Suzanne, Monge, Jorge, Kotb, Rami, Bahlis, Nizar, White, Darrell, Chen, Christine, Sutherland, Heather, Madan, Sumit, LeBlanc, Richard, Sebag, Michael, Venner, Christopher, Bensinger, William, Biran, Noa, DeCastro, Andrew, Van Domelen, Dane, Zhang, Chris, Shah, Jatin, Shacham, Sharon, Kauffman, Michael, Bentur, Ohad, and Lipe, Brea

Subjects
anti‐BCMA, multiple myeloma, selinexor
Abstract

There is a lack of consensus on therapy sequencing in previously treated multiple myeloma, particularly after anti-B-cell maturation antigen (BCMA) therapy. Earlier reports on selinexor (X) regimens demonstrated considerable efficacy in early treatment, and after anti-BCMA-targeted chimeric antigen receptor-T cell therapy. Here, we present data from 11 heavily pretreated patients who predominantly received BCMA-antibody-drug conjugate therapy. We observe that X-containing regimens are potent and achieve durable responses with numerically higher overall response and clinical benefit rates, as well as median progression free survival compared to patients prior anti-BCMA therapies, despite being used later in the treatment course. In an area of evolving unmet need, these data reaffirm the efficacy of X-based regimens following broader anti-BCMA therapy.

Published
2022

6. Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial

Author

Gounder, Mrinal M, Razak, Albiruni Abdul, Somaiah, Neeta, Chawla, Sant, Martin-Broto, Javier, Grignani, Giovanni, Schuetze, Scott M, Vincenzi, Bruno, Wagner, Andrew J, Chmielowski, Bartosz, Jones, Robin L, Riedel, Richard F, Stacchiotti, Silvia, Loggers, Elizabeth T, Ganjoo, Kristen N, Le Cesne, Axel, Italiano, Antoine, del Muro, Xavier Garcia, Burgess, Melissa, Piperno-Neumann, Sophie, Ryan, Christopher, Mulcahy, Mary F, Forscher, Charles, Penel, Nicolas, Okuno, Scott, Elias, Anthony, Hartner, Lee, Philip, Tony, Alcindor, Thierry, Kasper, Bernd, Reichardt, Peter, Lapeire, Lore, Blay, Jean-Yves, Chevreau, Christine, Morales, Claudia Maria Valverde, Schwartz, Gary K, Chen, James L, Deshpande, Hari, Davis, Elizabeth J, Nicholas, Garth, Gröschel, Stefan, Hatcher, Helen, Duffaud, Florence, Herráez, Antonio Casado, Beveridge, Roberto Diaz, Badalamenti, Giuseppe, Eriksson, Mikael, Meyer, Christian, von Mehren, Margaret, Van Tine, Brian A, Götze, Katharina, Mazzeo, Filomena, Yakobson, Alexander, Zick, Aviad, Lee, Alexander, Gonzalez, Anna Estival, Napolitano, Andrea, Dickson, Mark A, Michel, Dayana, Meng, Changting, Li, Lingling, Liu, Jianjun, Ben-Shahar, Osnat, Van Domelen, Dane R, Walker, Christopher J, Chang, Hua, Landesman, Yosef, Shah, Jatin J, Shacham, Sharon, Kauffman, Michael G, and Attia, Steven

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Genetics, Clinical Trials and Supportive Activities, Patient Safety, 6.1 Pharmaceuticals, Cancer, Child, Double-Blind Method, Humans, Hydrazines, Liposarcoma, Triazoles, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeAntitumor activity in preclinical models and a phase I study of patients with dedifferentiated liposarcoma (DD-LPS) was observed with selinexor. We evaluated the clinical benefit of selinexor in patients with previously treated DD-LPS whose sarcoma progressed on approved agents.MethodsSEAL was a phase II-III, multicenter, randomized, double-blind, placebo-controlled study. Patients age 12 years or older with advanced DD-LPS who had received two-five lines of therapy were randomly assigned (2:1) to selinexor (60 mg) or placebo twice weekly in 6-week cycles (crossover permitted). The primary end point was progression-free survival (PFS). Patients who received at least one dose of study treatment were included for safety analysis (ClinicalTrials.gov identifier: NCT02606461).ResultsTwo hundred eighty-five patients were enrolled (selinexor, n = 188; placebo, n = 97). PFS was significantly longer with selinexor versus placebo: hazard ratio (HR) 0.70 (95% CI, 0.52 to 0.95; one-sided P = .011; medians 2.8 v 2.1 months), as was time to next treatment: HR 0.50 (95% CI, 0.37 to 0.66; one-sided P < .0001; medians 5.8 v 3.2 months). With crossover, no difference was observed in overall survival. The most common treatment-emergent adverse events of any grade versus grade 3 or 4 with selinexor were nausea (151 [80.7%] v 11 [5.9]), decreased appetite (113 [60.4%] v 14 [7.5%]), and fatigue (96 [51.3%] v 12 [6.4%]). Four (2.1%) and three (3.1%) patients died in the selinexor and placebo arms, respectively. Exploratory RNA sequencing analysis identified that the absence of CALB1 expression was associated with longer PFS with selinexor compared with placebo (median 6.9 v 2.2 months; HR, 0.19; P = .001).ConclusionPatients with advanced, refractory DD-LPS showed improved PFS and time to next treatment with selinexor compared with placebo. Supportive care and dose reductions mitigated side effects of selinexor. Prospective validation of CALB1 expression as a predictive biomarker for selinexor in DD-LPS is warranted.

Published
2022

7. Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients

Author

Gasparetto, Cristina, Schiller, Gary J, Tuchman, Sascha A, Callander, Natalie S, Baljevic, Muhamed, Lentzsch, Suzanne, Rossi, Adriana C, Kotb, Rami, White, Darrell, Bahlis, Nizar J, Chen, Christine I, Sutherland, Heather J, Madan, Sumit, LeBlanc, Richard, Sebag, Michael, Venner, Christopher P, Bensinger, William I, Biran, Noa, Ammu, Sonia, Ben-Shahar, Osnat, DeCastro, Andrew, Van Domelen, Dane, Zhou, Tianjun, Zhang, Chris, Bentur, Ohad S, Shah, Jatin, Shacham, Sharon, Kauffman, Michael, and Lipe, Brea

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Rare Diseases, Cancer, Hematology, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Drug Administration Schedule, Female, Humans, Hydrazines, Male, Maximum Tolerated Dose, Middle Aged, Multiple Myeloma, Oligopeptides, Survival Analysis, Translocation, Genetic, Treatment Outcome, Triazoles, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundProteasome inhibitors (PIs), including carfilzomib, potentiate the activity of selinexor, a novel, first-in-class, oral selective inhibitor of nuclear export (SINE) compound, in preclinical models of multiple myeloma (MM).MethodsThe safety, efficacy, maximum-tolerated dose (MTD) and recommended phase 2 dose (RP2D) of selinexor (80 or 100 mg) + carfilzomib (56 or 70 mg/m2) + dexamethasone (40 mg) (XKd) once weekly (QW) was evaluated in patients with relapsed refractory MM (RRMM) not refractory to carfilzomib.ResultsThirty-two patients, median prior therapies 4 (range, 1-8), were enrolled. MM was triple-class refractory in 38% of patients and 53% of patients had high-risk cytogenetics del(17p), t(4;14), t(14;16) and/or gain 1q. Common treatment-related adverse events (all/Grade 3) were thrombocytopenia 72%/47% (G3 and G4), nausea 72%/6%, anaemia 53%/19% and fatigue 53%/9%, all expected and manageable with supportive care and dose modifications. MTD and RP2D were identified as selinexor 80 mg, carfilzomib 56 mg/m2, and dexamethasone 40 mg, all QW. The overall response rate was 78% including 14 (44%) ≥ very good partial responses. Median progression-free survival was 15 months.ConclusionsWeekly XKd is highly effective and well-tolerated. These data support further investigation of XKd in patients with MM.

Published
2022

8. Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.

Author

Richard, Shambavi, Chari, Ajai, Delimpasi, Sosana, Simonova, Maryana, Spicka, Ivan, Pour, Ludek, Kriachok, Iryna, Dimopoulos, Meletios, Pylypenko, Halyna, Auner, Holger, Leleu, Xavier, Usenko, Ganna, Hajek, Roman, Benjamin, Reuben, Dolai, Tuphan, Sinha, Dinesh, Venner, Christopher, Garg, Mamta, Stevens, Don, Quach, Hang, Jagannath, Sundar, Moreau, Phillipe, Levy, Moshe, Badros, Ashraf, Anderson, Larry, Bahlis, Nizar, Facon, Thierry, Mateos, Maria, Cavo, Michele, Chang, Hua, Landesman, Yosef, Chai, Yi, Arazy, Melina, Shah, Jatin, Shacham, Sharon, Kauffman, Michael, Grosicki, Sebastian, and Richardson, Paul

Subjects
Adult, Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Bortezomib, Cytogenetic Analysis, Dexamethasone, Female, Humans, Hydrazines, Male, Middle Aged, Multiple Myeloma, Progression-Free Survival, Treatment Outcome, Triazoles, Young Adult
Abstract

In the phase 3 BOSTON study, patients with multiple myeloma (MM) after 1-3 prior regimens were randomized to once-weekly selinexor (an oral inhibitor of exportin 1 [XPO1]) plus bortezomib-dexamethasone (XVd) or twice-weekly bortezomib-dexamethasone (Vd). Compared with Vd, XVd was associated with significant improvements in median progression-free survival (PFS), overall response rate (ORR), and lower rates of peripheral neuropathy, with trends in overall survival (OS) favoring XVd. In BOSTON, 141 (35.1%) patients had MM with high-risk (presence of del[17p], t[4;14], t[14;16], or ≥4 copies of amp1q21) cytogenetics (XVd, n = 70; Vd, n = 71), and 261 (64.9%) exhibited standard-risk cytogenetics (XVd, n = 125; Vd, n = 136). Among patients with high-risk MM, median PFS was 12.91 months for XVd and 8.61 months for Vd (HR, 0.73 [95% CI, (0.4673, 1.1406)], p = 0.082), and ORRs were 78.6% and 57.7%, respectively (OR 2.68; p = 0.004). In the standard-risk subgroup, median PFS was 16.62 months for XVd and 9.46 months for Vd (HR 0.61; p = 0.004), and ORRs were 75.2% and 64.7%, respectively (OR 1.65; p = 0.033). The safety profiles of XVd and Vd in both subgroups were consistent with the overall population. These data suggest that selinexor can confer benefits to patients with MM regardless of cytogenetic risk. ClinicalTrials.gov identifier: NCT03110562.

Published
2021

11. Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myeloma.

Author

Richardson, Paul, Jagannath, Sundar, Chari, Ajai, Vogl, Dan, Dimopoulos, Meletios, Moreau, Philippe, Dingli, David, Wei, Lee-Jen, Richter, Joshua, Biran, Noa, Siegel, David, Reichmann, William, Li, Lingling, Tang, Shijie, Saint-Martin, Jean-Richard, Joshi, Anita, Kauffman, Michael, Shah, Jatin, Shacham, Sharon, and Lonial, Sagar

Subjects
multiple myeloma, selective inhibitor of nuclear export, selinexor, triple‐class‐refractory multiple myeloma
Abstract

Triple-class-refractory multiple myeloma (MM) describes MM refractory to proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies. In the Phase IIb STORM study (NCT02336815), oral selinexor plus low-dose dexamethasone (Sel-dex) demonstrated a 26.2% overall response rate in triple-class-refractory MM. Here, we compare overall survival (OS) of 122 patients with triple-class-refractory MM who received Sel-dex in STORM Part 2 with that of 64 similar patients treated with other available therapies in a Flatiron Health Analytic Database (FHAD) cohort. OS from the date that the patients MM became triple-class-refractory was longer in STORM versus FHAD, with an unadjusted hazard ratio (HR) of 0.43 (P =  .0002; adjusted HR 0.35 [P  =  .011]). In a subset analysis of highly resistant patients receiving further therapies after their MM first became at least triple-class-refractory (i.e., who received Sel-dex in STORM, n = 64, and non-Sel-dex in FHAD, n = 36), the OS was significantly longer in STORM with an unadjusted HR of 0.52 (P = .0331; adjusted HR 0.33 [P = .041]). Within the limits of this analysis, the OS of patients with at least triple-class-refractory MM was significantly better with Sel-dex versus available therapies, suggesting that Sel-dex may be associated with a meaningful OS benefit in these patients.

Published
2021

13. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials.

Author

Gavriatopoulou, Maria, Chari, Ajai, Chen, Christine, Bahlis, Nizar, Vogl, Dan, Jakubowiak, Andrzej, Dingli, David, Cornell, Robert, Hofmeister, Craig, Siegel, David, Berdeja, Jesus, Reece, Donna, White, Darrell, Lentzsch, Suzanne, Gasparetto, Cristina, Huff, Carol, Jagannath, Sundar, Baz, Rachid, Nooka, Ajay, Richter, Joshua, Abonour, Rafat, Parker, Terri, Yee, Andrew, Moreau, Philippe, Lonial, Sagar, Tuchman, Sascha, Weisel, Katja, Mohty, Mohamad, Choquet, Sylvain, Unger, T, Li, Kai, Chai, Yi, Li, Lingling, Shah, Jatin, Shacham, Sharon, Kauffman, Michael, and Dimopoulos, Meletios

Subjects
Aged, Antineoplastic Agents, Appetite, Clinical Trials as Topic, Diarrhea, Fatigue, Female, Humans, Hydrazines, Hyponatremia, Male, Middle Aged, Multiple Myeloma, Nausea, Thrombocytopenia, Triazoles
Abstract

Selinexor is an oral, small molecule inhibitor of the nuclear export protein exportin 1 with demonstrated activity in hematologic and solid malignancies. Side effects associated with selinexor include nausea, vomiting, fatigue, diarrhea, decreased appetite, weight loss, thrombocytopenia, neutropenia, and hyponatremia. We reviewed 437 patients with multiple myeloma treated with selinexor and assessed the kinetics of adverse events and impact of supportive care measures. Selinexor reduced both platelets and neutrophils over the first cycle of treatment and reached a nadir between 28 and 42 days. Platelet transfusions and thrombopoietin receptor agonists were effective at treating thrombocytopenia, and granulocyte colony stimulating factors were effective at resolving neutropenia. The onset of gastrointestinal side effects (nausea, vomiting, and diarrhea) was most common during the first 1-2 weeks of treatment. Nausea could be mitigated with 5-HT3 antagonists and either neurokinin 1 receptor antagonists, olanzapine, or cannbainoids. Loperamide and bismuth subsalicylate ameliorated diarrhea. The primary constitutional side effects of fatigue and decreased appetite could be managed with methylphenidate, megestrol, cannabinoids or olanzapine, respectively. Hyponatremia was highly responsive to sodium replacement. Selinexor has well-established adverse effects that mainly occur within the first 8 weeks of treatment, are reversible, and respond to supportive care.

Published
2020

15. Preoperative Evaluation of Thyroid Cancer: A Review of Current Best Practices

Author

Russell, Marika D., Shonka, David C., Jr., Noel, Julia, Karcioglu, Amanda Silver, Ahmed, Amr H., Angelos, Peter, Atkins, Kristen, Bischoff, Lindsay, Buczek, Erin, Caulley, Lisa, Freeman, Jeremy, Kroeker, Teresa, Liddy, Whitney, McIver, Bryan, McMullen, Caitlin, Nikiforov, Yuri, Orloff, Lisa, Scharpf, Joseph, Shah, Jatin, Shaha, Ashok, Singer, Michael, Tolley, Neil, Tuttle, Robert Michael, Witterick, Ian, and Randolph, Gregory W.

Published
2023
Full Text
View/download PDF

17. Parotidectomy for deep lobe pleomorphic adenomas is associated with higher rates of complications and recurrence

Author

Levyn, Helena, primary, Subramanian, Tejas, additional, Eagan, Alana, additional, Katabi, Nora, additional, Goldberg, Johanna, additional, Scholfield, Daniel W., additional, Caxeiro, Giovanna L., additional, Wong, Richard J., additional, Cohen, Marc A., additional, Shah, Jatin P., additional, Patel, Snehal G., additional, and Ganly, Ian, additional

Published
2024
Full Text
View/download PDF

19. Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study

Author

Schuster, Michael, Zijlstra, Josée, Casasnovas, Rene-Olivier, Vermaat, Joost S.P, Kalakonda, Nagesh, Goy, Andre, Choquet, Sylvain, Neste, Eric Van Den, Hill, Brian, Thieblemont, Catherine, Cavallo, Federica, De la Cruz, Fatima, Kuruvilla, John, Hamad, Nada, Jaeger, Ulrich, Caimi, Paolo, Gurion, Ronit, Warzocha, Krzysztof, Bakhshi, Sameer, Sancho, Juan-Manuel, Follows, George, Egyed, Miklos, Offner, Fritz, Vassilakopoulos, Theodoros, Samal, Priyanka, Ku, Matthew, Ma, Xiwen, Corona, Kelly, Chamoun, Kamal, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G., Canales, Miguel, and Maerevoet, Marie

Published
2022
Full Text
View/download PDF

20. Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study

Author

Thein, Kyaw Z., Karp, Daniel D., Tsimberidou, Apostolia, Gong, Jing, Sulovic, Selma, Shah, Jatin, Milton, Denái R., Hong, David S., Janku, Filip, McQuinn, Lacey, Stephen, Bettzy A., Colen, Rivka, Carter, Brett W., Yap, Timothy A., Piha-Paul, Sarina A., Fu, Siqing, Meric-Bernstam, Funda, and Naing, Aung

Published
2022
Full Text
View/download PDF

25. Skull base surgery for malignant tumors: The 2nd international collaborative study (1995–2015).

Author

Shah, Jatin P., Levyn, Helena, Valero, Cristina, Adilbay, Dauren, Eagan, Alana, Zheng, Junting, Gonen, Mithat, Cohen, Marc, Patel, Snehal, Ganly, Ian, Pai, Prathamesh, Castelnuovo, Paolo, Gao, Fang Ju, Piazza, Cesare, Nicolai, Piero, Panizza, Ben, Bowman, James, Barnett, Catherine, Kowalski, Luiz P., and Toledo, Ronaldo

Subjects
SKULL base, SURVIVAL rate, SKULL surgery, SKULL tumors, ENDOSCOPIC surgery
Abstract

Background: The current study presents the effort of a global collaborative group to review the management and outcomes of malignant tumors of the skull base worldwide. Patients and methods: A total of 28 institutions contributed data on 3061 patients. Analysis evaluated clinical variables, survival outcomes, and multivariable factors associated with outcomes. Results: The median age was 56 years (IQR 44–67). The open surgical approach was used in 55% (n = 1680) of cases, endoscopic resection was performed in 36% (n = 1087), and the combined approach in 9.6% (n = 294). With a median follow‐up of 7.1 years, the 5‐year OS DSS and RFS were 65%, 71.7% and 53%, respectively. On multivariable analysis, older age, comorbidities, histology, dural/intracranial involvement, positive margins, advanced stage, and primary site were independent prognostic factors for OS, DSS, and RFS. Adjuvant RT was a protective prognostic factor. Conclusion: The progress across various disciplines may have contributed to improved OS and DSS in this study compared to previous reports. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes

Author

Casasnovas, Rene-Olivier, Follows, George, Zijlstra, Josee M., Vermaat, Joost S.P., Kalakonda, Nagesh, Choquet, Sylvain, Neste, Eric Van Den, Hill, Brian, Thieblemont, Catherine, Cavallo, Federica, la Cruz, Fatima De, Kuruvilla, John, Hamad, Nada, Jaeger, Ulrich, Caimi, Paolo F., Gurion, Ronit, Warzocha, Krzysztof, Bakhshi, Sameer, Sancho, Juan-Manuel, Schuster, Michael, Egyed, Miklos, Offner, Fritz, Vassilakopoulos, Theodoros P., Samal, Priyanka, Ku, Matthew, Ma, Xiwen, Chamoun, Kamal, Shah, Jatin, Canales, Miguel, Maerevoet, Marie, Shacham, Sharon, Kauffman, Michael G., and Goy, Andre

Published
2022
Full Text
View/download PDF

30. NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018.

Author

Colevas, A Dimitrios, Yom, Sue S, Pfister, David G, Spencer, Sharon, Adelstein, David, Adkins, Douglas, Brizel, David M, Burtness, Barbara, Busse, Paul M, Caudell, Jimmy J, Cmelak, Anthony J, Eisele, David W, Fenton, Moon, Foote, Robert L, Gilbert, Jill, Gillison, Maura L, Haddad, Robert I, Hicks, Wesley L, Hitchcock, Ying J, Jimeno, Antonio, Leizman, Debra, Maghami, Ellie, Mell, Loren K, Mittal, Bharat B, Pinto, Harlan A, Ridge, John A, Rocco, James, Rodriguez, Cristina P, Shah, Jatin P, Weber, Randal S, Witek, Matthew, Worden, Frank, Zhen, Weining, Burns, Jennifer L, and Darlow, Susan D

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Dental/Oral and Craniofacial Disease, Digestive Diseases, Cancer, Guidelines as Topic, Head and Neck Neoplasms, History, 21st Century, Humans, Oncology & Carcinogenesis, Oncology and carcinogenesis, Health services and systems
Abstract

The NCCN Guidelines for Head and Neck (H&N) Cancers provide treatment recommendations for cancers of the lip, oral cavity, pharynx, larynx, ethmoid and maxillary sinuses, and salivary glands. Recommendations are also provided for occult primary of the H&N, and separate algorithms have been developed by the panel for very advanced H&N cancers. These NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding evaluation and treatment of nasopharyngeal carcinoma.

Published
2018

32. Recurrent Laryngeal Nerve Intraoperative Neuromonitoring Indications in Non-Thyroid and Non-Parathyroid Surgery

Author

Brunet, Aina, primary, Rovira, Aleix, additional, Quer, Miquel, additional, Sanabria, Alvaro, additional, Guntinas-Lichius, Orlando, additional, Zafereo, Mark, additional, Hartl, Dana M., additional, Coca-Pelaz, Andrés, additional, Shaha, Ashok R., additional, Marie, Jean-Paul, additional, Vander Poorten, Vincent, additional, Piazza, Cesare, additional, Kowalski, Luiz P., additional, Randolph, Gregory W., additional, Shah, Jatin P., additional, Rinaldo, Alessandra, additional, and Simo, Ricard, additional

Published
2024
Full Text
View/download PDF

35. Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi‐arm phase Ib study

Author

Thein, Kyaw Zin, Piha-Paul, Sarina A., Tsimberidou, Apostolia, Karp, Daniel D., Janku, Filip, Zarifa, Abdulrazzak, Shah, Jatin, Milton, Denái R., Bean, Stacie, McQuinn, Lacey, Gong, Jing, Colen, Rivka, Carter, Brett W., Subbiah, Vivek, Ogbonna, Deby C., Pant, Shubham, Meric-Bernstam, Funda, and Naing, Aung

Published
2021
Full Text
View/download PDF

39. NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017.

Author

Adelstein, David, Gillison, Maura L, Pfister, David G, Spencer, Sharon, Adkins, Douglas, Brizel, David M, Burtness, Barbara, Busse, Paul M, Caudell, Jimmy J, Cmelak, Anthony J, Colevas, A Dimitrios, Eisele, David W, Fenton, Moon, Foote, Robert L, Gilbert, Jill, Haddad, Robert I, Hicks, Wesley L, Hitchcock, Ying J, Jimeno, Antonio, Leizman, Debra, Lydiatt, William M, Maghami, Ellie, Mell, Loren K, Mittal, Bharat B, Pinto, Harlan A, Ridge, John A, Rocco, James, Rodriguez, Cristina P, Shah, Jatin P, Weber, Randal S, Witek, Matthew, Worden, Frank, Yom, Sue S, Zhen, Weining, Burns, Jennifer L, and Darlow, Susan D

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Dental/Oral and Craniofacial Disease, Cancer, Digestive Diseases, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Head and Neck Neoplasms, Humans, Oncology & Carcinogenesis, Oncology and carcinogenesis, Health services and systems
Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Head and Neck Cancers provide treatment recommendations for cancers of the lip, oral cavity, pharynx, larynx, ethmoid and maxillary sinuses, and salivary glands. Recommendations are also provided for occult primary of the head and neck (H&N), and separate algorithms have been developed by the panel for very advanced H&N cancers. These NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding the increase in human papillomavirus-associated oropharyngeal cancer and the availability of immunotherapy agents for treatment of patients with recurrent or metastatic H&N cancer.

Published
2017

43. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial

Author

Kalakonda, Nagesh, Maerevoet, Marie, Cavallo, Federica, Follows, George, Goy, Andre, Vermaat, Joost S P, Casasnovas, Olivier, Hamad, Nada, Zijlstra, Josée M, Bakhshi, Sameer, Bouabdallah, Reda, Choquet, Sylvain, Gurion, Ronit, Hill, Brian, Jaeger, Ulrich, Sancho, Juan Manuel, Schuster, Michael, Thieblemont, Catherine, De la Cruz, Fátima, Egyed, Miklos, Mishra, Sourav, Offner, Fritz, Vassilakopoulos, Theodoros P, Warzocha, Krzysztof, McCarthy, Daniel, Ma, Xiwen, Corona, Kelly, Saint-Martin, Jean-Richard, Chang, Hua, Landesman, Yosef, Joshi, Anita, Wang, Hongwei, Shah, Jatin, Shacham, Sharon, Kauffman, Michael, Van Den Neste, Eric, and Canales, Miguel A

Published
2020
Full Text
View/download PDF

45. Response to Letter to the Editor From Jagannath and Mayilvaganan: “Is Multifocality a Predictor of Poor Outcome in Childhood and Adolescent Papillary Thyroid Carcinoma?”

Author

Scholfield, Daniel W, primary, Lopez, Joseph, additional, Eagan, Alana, additional, Antal, Zoltan, additional, Tuttle, R Michael, additional, Ghossein, Ronald, additional, LaQuaglia, Michael, additional, Shaha, Ashok R, additional, Shah, Jatin P, additional, Wong, Richard J, additional, Patel, Snehal G, additional, and Ganly, Ian, additional

Published
2024
Full Text
View/download PDF

47. Hypoxia-Directed Treatment of Human Papillomavirus–Related Oropharyngeal Carcinoma

Author

Lee, Nancy Y., primary, Sherman, Eric J., additional, Schöder, HeiKo, additional, Wray, Rick, additional, Boyle, Jay O., additional, Singh, Bhuvanesh, additional, Grkovski, Milan, additional, Paudyal, Ramesh, additional, Cunningham, Louise, additional, Zhang, Zhigang, additional, Hatzoglou, Vaios, additional, Katabi, Nora, additional, Diplas, Bill H., additional, Han, James, additional, Imber, Brandon S., additional, Pham, Khoi, additional, Yu, Yao, additional, Zakeri, Kaveh, additional, McBride, Sean M., additional, Kang, Jung J., additional, Tsai, C. Jillian, additional, Chen, Linda C., additional, Gelblum, Daphna Y., additional, Shah, Jatin P., additional, Ganly, Ian, additional, Cohen, Marc A., additional, Cracchiolo, Jennifer R., additional, Morris, Luc G.T., additional, Dunn, Lara A., additional, Michel, Loren S., additional, Fetten, James V., additional, Kripani, Anuja, additional, Pfister, David G., additional, Ho, Alan L., additional, Shukla-Dave, Amita, additional, Humm, John L., additional, Powell, Simon N., additional, Li, Bob T., additional, Reis-Filho, Jorge S., additional, Diaz, Luis A., additional, Wong, Richard J., additional, and Riaz, Nadeem, additional

Published
2024
Full Text
View/download PDF

49. Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity‐modulated radiotherapy

Author

Pan, Jian Ji, Ng, Wai Tong, Zong, Jing Feng, Lee, Sarah WM, Choi, Horace CW, Chan, Lucy LK, Lin, Shao Jun, Guo, Qiao Juan, Sze, Henry CK, Bin Chen, Yun, Xiao, You Ping, Kan, Wai Kuen, O'Sullivan, Brian, Xu, Wei, Le, Quynh Thu, Glastonbury, Christine M, Colevas, A Dimitrios, Weber, Randal S, Lydiatt, William, Shah, Jatin P, and Lee, Anne WM

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Cancer, Adolescent, Adult, Aged, Aged, 80 and over, Child, Female, Follow-Up Studies, Humans, L-Lactate Dehydrogenase, Male, Middle Aged, Nasopharyngeal Neoplasms, Neoplasm Staging, Nomograms, Prognosis, Radiotherapy, Intensity-Modulated, Retrospective Studies, Survival Rate, Young Adult, intensity-modulated radiotherapy, nasopharyngeal carcinoma, nomogram, prognostication, TNM staging, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis, Public health
Abstract

BackgroundThe objective of this study was to develop a nomogram for refining prognostication for patients with nondisseminated nasopharyngeal cancer (NPC) staged with the proposed 8th edition of the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) staging system.MethodsConsecutive patients who had been investigated with magnetic resonance imaging, staged with the proposed 8th edition of the AJCC/UICC staging system, and irradiated with intensity-modulated radiotherapy from June 2005 to December 2010 were analyzed. A cohort of 1197 patients treated at Fujian Provincial Cancer Hospital was used as the training set, and the results were validated with 412 patients from Pamela Youde Nethersole Eastern Hospital. Cox regression analyses were performed to identify significant prognostic factors for developing a nomogram to predict overall survival (OS). The discriminative ability was assessed with the concordance index (c-index). A recursive partitioning algorithm was applied to the survival scores of the combined set to categorize the patients into 3 risk groups.ResultsA multivariate analysis showed that age, gross primary tumor volume, and lactate dehydrogenase were independent prognostic factors for OS in addition to the stage group. The OS nomogram based on all these factors had a statistically higher bias-corrected c-index than prognostication based on the stage group alone (0.712 vs 0.622, P

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results